Endoscopic Bariatric and Metabolic Therapies: New and Emerging Technologies

Gastroenterology

Volumn 152, Issue 7, 2017, Pages 1791-1801

  Sullivan, Shelby ^a   Edmundowicz, Steven A ^a   Thompson, Christopher C ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aspiration Therapy; Duodenal Mucosal Resurfacing; Duodenojejunal Bypass Liner; Endoscopic Bariatric Therapy; Endoscopic Sleeve Gastroplasty; Gastroduodenojejunal Bypass Sleeve; Incisionless Magnet Anastomosis System; Intragastric Balloons; Primary Surgery Obesity Endoluminal; Transpyloric Shuttle

Indexed keywords

ARTICLE; BARIATRICS; DIABETES MELLITUS; DIGESTIVE DEVICE; ENDOSCOPIC THERAPY; ENDOSCOPY; GASTRIC BALLOON; GLUCOSE INTOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OBESITY; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALL INTESTINE; STOMACH; TECHNOLOGY; TREATMENT INDICATION; UNITED STATES; WEIGHT REDUCTION; ABLATION THERAPY; BARIATRIC SURGERY; DEVICES; DUODENUM; GASTROINTESTINAL ENDOSCOPY; GASTROPLASTY; INTESTINE MUCOSA; PROCEDURES; SUCTION; SURGERY; SUTURE TECHNIQUE;

ABLATION TECHNIQUES; BARIATRIC SURGERY; DUODENUM; ENDOSCOPY, GASTROINTESTINAL; GASTROPLASTY; HUMANS; INTESTINAL MUCOSA; OBESITY; SUCTION; SUTURE TECHNIQUES;

EID: 85018657923     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.01.044     Document Type: Article

References (53)

1. 1 Ponce, J., Woodman, G., Swain, J., et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 11 (2015), 874–881.
2. 2 Abu Dayyeh, B.K., Kumar, N., Edmundowicz, S.A., et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 82 (2015), 425–438.e5.
3. 3 Farina, M.G., Baratta, R., Nigro, A., et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg 22 (2012), 565–571.
4. 4 Chang, S., Stoll, C.T., Song, J., et al. The effectiveness and risks of bariatric surgery: An updated systematic review and meta-analysis, 2003-2012. JAMA Surg 149 (2014), 275–287.
5. 5 Ali, M.R., Moustarah, F., Kim, J.J., American Society for Metabolic and Bariatric Surgery position statement on intragastric balloon therapy endorsed by the Society of American Gastrointestinal and Endoscopic Surgeons. Surg Obes Relat Dis 12 (2016), 462–467.
6. 6 Sullivan, S., Kumar, N., Edmundowicz, S.A., et al. ASGE position statement on endoscopic bariatric therapies in clinical practice. Gastrointest Endosc 82 (2015), 767–772.
7. 7 Geliebter, A., Westreich, S., Gage, D., Gastric distention by balloon and test-meal intake in obese and lean subjects. Am J Clin Nutr 48 (1988), 592–594.
8. 8 Gómez, V., Woodman, G., Abu Dayyeh, B.K., Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity 24 (2016), 1849–1853.
9. 9 Martinez-Brocca, M.A., Belda, O., Parejo, J., et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg 17 (2007), 649–657.
10. 10 Mathus-Vliegen, E.M.H., Eichenberger, R.I., Fasting and meal-suppressed ghrelin levels before and after intragastric balloons and balloon-induced weight loss. Obes Surg 24 (2014), 85–94.
11. 11 Mathus-Vliegen, E.M., de Groot, G.H., Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity. Obes Surg 23 (2013), 622–633.
12. 12 US Food and Drug Administration. Summary of safety and effectiveness data (SSED) ORBERA Intragastric Balloon System. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140008b.pdf. 2015:1-32.
13. 13 US Food and Drug Administration. Summary of safety and effectiveness data (SSED): Obalon Balloon System. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160001b.pdf. 2016:1-46.
14. 14 Kotzampassi, K., Grosomanidis, V., Papakostas, P., et al. 500 intragastric balloons: what happens 5 years thereafter?. Obes Surg 22 (2012), 896–903.
15. 15 Benjamin, S.B., Small bowel obstruction and the Garren-Edwards gastric bubble: an iatrogenic bezoar. Gastrointest Endosc 34 (1988), 463–467.
16. 16 Benjamin, S.B., Maher, K.A., Cattau, E.L. Jr., et al. Double-blind controlled trial of the Garren-Edwards gastric bubble: an adjunctive treatment for exogenous obesity. Gastroenterology 95 (1988), 581–588.
17. 17 Hogan, R.B., Johnston, J.H., Long, B.W., et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc 35 (1989), 381–385.
18. 18 Zeman, R.K., Benjamin, S.B., Cunningham, M.B., et al. Small bowel obstruction due to Garren gastric bubble: radiographic diagnosis. AJR Am J Roentgenol 150 (1988), 581–582.
19. 19 Abu Dayyeh, B.K., Eaton, L.L., Woodman, G., et al. 444 A Randomized, Multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subjects. Gastrointest Endosc, 81, 2015, AB147.
20. 20 US Food and Drug Administration. Summary of safety and effectiveness data (SSED) ReShape Integrated Dual Balloon System. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140012b.pdf. 2015:1-43.
21. 21 Sullivan, S., Swain, J.M., Woodman, G., et al. 812d The Obalon Swallowable 6-Month Balloon System is more effective than moderate intensity lifestyle therapy alone: results from a 6- month randomized sham controlled trial. Gastroenterology, 150, 2016, S1267.
22. 22 Thompson, C.C., Abu Dayyeh, B.K., Kushner, R., et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol 112 (2017), 447–457.
23. 23 Sullivan, S., Swain, J.M., Woodman, G., et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial. Obesity (Silver Spring) 25 (2017), 294–301.
24. 24 Jensen, M.D., Ryan, D.H., Apovian, C.M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129 (2014), S102–S138.
25. 25 Lopez-Nava, G., Bautista-Castaño, I., Jimenez-Baños, A., et al. Dual intragastric balloon: single ambulatory center Spanish experience with 60 patients in endoscopic weight loss management. Obes Surg 25 (2015), 2263–2267.
26. 26 Machytka, E., Klvana, P., Kornbluth, A., et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg 21 (2011), 1499–1507.
27. 27 Brooks, J., Srivastava, E.D., Mathus-Vliegen, E.M., One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg 24 (2014), 813–819.
28. 28 Chuttani, R., Machytka, E., Raftopoulos, I., et al. 102 The first procedureless gastric balloon for weight loss: final results from a multi-center, prospective study evaluating safety, efficacy, metabolic parameters, quality of life, and 6-month follow-up. Gastroenterology, 150, 2016, S26.
29. 29 Haskins O. TransPyloric Shuttle demonstrates weight loss. Bariatric News. Available at: http://www.bariatricnews.net/?q=node/1236. 2013.
30. 30 Sullivan, S., Stein, R., Jonnalagadda, S., et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 145 (2013), 1245–1252.e5.
31. 31 Machytka, E., Turro, R., Huberty, V., et al. Mo1944 Aspiration therapy in super obese patients - pilot trial. Gastroenterology 150 (2016), S822–S823.
32. 32 US Food and Drug Administration. Sumary of safety and effectiveness data (SSED): AspireAssist. Available atr: https://www.accessdata.fda.gov/cdrh_docs/pdf15/p150024b.pdf. FDA, ed, 2016:1-36.
33. 33 Espinós, J.C., Turró, R., Moragas, G., et al. Gastrointestinal physiological changes and their relationship to weight loss following the pose procedure. Obes Surg 26 (2016), 1081–1089.
34. 34 Abu Dayyeh, B.K., Acosta, A., Camilleri, M., et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol 15 (2017), 37–43.e1.
35. 35 Miller, K., Turró, R., Greve, J.W., et al. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose SM vs. medical therapy. Obes Surg 27 (2017), 310–322.
36. 36 López-Nava, G., Bautista-Castaño, I., Jimenez, A., et al. The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis 11 (2015), 861–865.
37. 37 Lopez-Nava, G., Sharaiha, R.Z., Galvao Neto, M., et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 242 patients with 18 months follow-up. Gastroenterology, 150(4S1), 2016, S26.
38. 38 Kumar, N., Lopez-Nava, G., Sahdala, H.N.P., et al. 934 Endoscopic sleeve gastroplasty: multicenter weight loss results. Gastroenterology, 148, 2015, S179.
39. 39 Pories, W.J., Swanson, M.S., MacDonald, K.G., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222 (1995), 339–350 discussion 350-352.
40. 40 Rubino, F., Gagner, M., Gentileschi, P., et al. The early effect of the roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240 (2004), 236–242.
41. 41 Klein, S., Fabbrini, E., Patterson, B.W., et al. Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes. Obesity 20 (2012), 1266–1272.
42. ® in grade I obese patients with long-standing type 2 diabetes: role of gastrointestinal hormones in glucose metabolism. Obes Surg 27 (2017), 569–577.
43. 43 Koehestanie, P., Dogan, K., Berends, F., et al. Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, accompanied by elevated fasting ghrelin levels. Endosc Int Open 2 (2014), E21–E27.
44. 44 de Jonge, C., Rensen, S.S., Verdam, F.J., et al. Endoscopic duodenal–jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg 23 (2013), 1354–1360.
45. ®) on gastric emptying in obese and type 2 diabetic patients. Obes Surg 25 (2015), 1618–1625.
46. 46 Zechmeister-Koss, I., Huić, M., Fischer, S., The duodenal–jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review. Obes Surg 24 (2014), 310–323.
47. 47 Kaplan LM, Buse JB, Mullin C, et al. EndoBarrier therapy is associated with glycemic improvement, weight loss and safety issues in patients with obesity and type 2 diabetes on oral antihyperglycemic agents. American Diabetes Association 76th Scientific Sessions, New Orleans, LA, 2016.
48. 48 Peter, S., Monkemuller, K., Ablative endoscopic therapies for Barrett's esophagus-related neoplasia. Gastroenterol Clin North Am 44 (2015), 337–353.
49. 49 Rajagopalan, H., Cherrington, A.D., Thompson, C.C., et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care 39 (2016), 2254–2261.
50. 50 Sandler, B.J., Rumbaut, R., Swain, C.P., et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc 25 (2011), 3028–3033.
51. 51 Sandler, B.J., Rumbaut, R., Swain, C.P., et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc 29 (2015), 3298–3303.
52. 52 Machytka, E., Buzga, M., Lautz, D.B., et al. 103 A dual-path enteral bypass procedure created by a novel incisionless anastomosis system (IAS): 6-month clinical results. Gastroenterology, 150, 2016, S26.
53. 53 Machytka, E., Buzga, M., Ryou, M., et al. 1139 Endoscopic dual-path enteral anastomosis using self-assembling magnets: first-in-human clinical feasibility. Gastroenterology, 150, 2016, S232.